ID   REME011-2
AC   CVCL_E3Q4
SY   REME011; REME11-2; REME11; F_PDO_000063
DR   CancerTools; 160911
RX   PubMed=29917168;
WW   Info; FTRP; -; https://www.fmu.ac.jp/home/trc/en/contract-research-provision/f-pdo/
CC   Group: Cancer organoid.
CC   Part of: Fukushima Translational Research Project Patient-Derived Organoids (F-PDO) collection.
CC   Population: Japanese.
CC   Doubling time: ~8 days (PubMed=29917168).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C8028; Endometrial clear cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   79Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 14-08-25; Version: 3
//
RX   PubMed=29917168; DOI=10.3892/or.2018.6501; PMCID=PMC6072291;
RA   Tamura, Hirosumi
RA   Higa, Arisa
RA   Hoshi, Hirotaka
RA   Hiyama, Gen
RA   Takahashi, Nobuhiko
RA   Ryufuku, Masae
RA   Morisawa, Gaku
RA   Yanagisawa, Yuka
RA   Ito, Emi
RA   Imai, Jun-ichi
RA   Dobashi, Yuu
RA   Katahira, Kiyoaki
RA   Soeda, Shu
RA   Watanabe, Takafumi
RA   Fujimori, Keiya
RA   Watanabe, Shinya
RA   Takagi, Motoki
RT   "Evaluation of anticancer agents using patient-derived tumor organoids
RT   characteristically similar to source tissues.";
RL   Oncol. Rep. 40:635-646(2018).
//